News

2019

Sequana Medical announces first patient enrolled in North American alfapump® pivotal study (POSEIDON)

25 September 2019

FierceBiotech names Confo Therapeutics as one of its “Fierce 15” Biotech Companies of 2019

23 September 2019

iSTAR Medical announces € 40 million Series C financing

5 September 2019

Mainstay Medical announces completion of financing transactions

30 July 2019

iSTAR Medical’s MINIject shows consistent results at 18-month follow-up in first-in-human trial (STAR-I)

10 July 2019

Confo Therapeutics and DyNAbind announce drug discovery collaboration to identify novel GPCR-modulating compounds

3 July 2019

Mainstay Medical announces completion of pre-submission meeting with FDA regarding Pre-Market Approval (PMA) application for ReActiv8

26 June 2019

Confo Therapeutics raises € 30 million in Series A financing

7 May 2019

Professor Paul Fitzgerald joins Nexstim’s Scientific Advisory Board

24 April 2019

2018

iSTAR Medical’s MINIject maintains exceptional results in first-in-human trial one year post-surgery (STAR-I)

19 December 2018

UK NICE recommends use of Sequana's alfapump® for the treatment of refractory ascites caused by cirrhosis under special arrangements

15 November 2018

Sequana Medical establishes new corporate headquarters in Ghent, Belgium and raises € 8.5 million from leading Belgian investors including Newton Biocapital, PMV and SFPI-FPIM as well as existing shareholders

15 October 2018

• 1
• 2
• 3
• 4
• 5